Reata raises $78 million to fund second pivotal bardoxolone trial as it seeks European partner
This article was originally published in Scrip
Reata Pharmaceuticals has raised $78 million to fund the second of two pivotal trials of its lead product candidate bardoxolone methyl (RTA 402) in patients with advanced chronic kidney disease (CKD) and type 2 diabetes.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.